Another COVID-19 vaccine seeks approval for use in USA

SPECIALIST. THANKS FOR BEING HERE. >> THE OYNL CHOICE MOST AMERICANS HAVE RIGHT NOW IS BETWEEN PFIZER AND MODERNA. THEY REVIEWED AN APPLICATION FROM NOVAVAX, HOW IS THAT VACCINE DIFFERENT FROM THE ONES THAT ARE ALREADY OUT THERE? >> THIS VACCINE IS MADE AND CALLED A PROTEINS SUB FRUITED VACCINE. SIMILAR TOHE T FLU VACCINE FOR HEPATITIS B, TAKES THE PROTEIN FROM OUTSIDE OF THE VIRUS AND PUTS IT IN A NANO PARTICLE. SO THIS IS FOR A COMPROMEIS PEOPLE, IT MAY BE MORE ACCEPTABLE TO SOME PEOPLE WHO HAVE NOT YET ACCEPTED VACCINATIONS. >> BUT CAN YOU TELLS U ABOUT DOSING, EFFICACY? >> IT’SWO T DOSES THREE WEEKS APART, SIMILAR TO THE OTHER VACCINES, THE EFFICACY IS VERY GOOD, ABOVE 90%, AND NOBODY IN THE TALRI GOT SEVERE OR MODERATE COVID, SO IT LOOKS VERY SIMILAR ADVOCACY TO WHAT WE HAVE TO THE OTHERS THAT ARE AVAILABLE. N: THE NOVAVAX VACCINE HAS BEEN AUTHORIZED, INCLUDING THE EUROPEAN UNION, THE U.K. IN CANADA. WHAT TKOO LONG PERIOD AND ARE THERE SAFETY CONCERNS? >> DURING YOUR — THE REASON IT OKTO LONGER HERE IS BECAUSE OF MANUFACTURING IN THE STRATEGY THE COMPANY TOOK IN STARTING OUTSIDE THE U.S.. IN TERMS OF SAFETY, THERE HAVE BEEN REPORTS OF THE HEART INFLAMMATION THAT WE HAVE SEEN WITH OTHER VACCINES, AND WHETHER THAT’S REAL, A HIGHER INCIDENCE ARE A REFLECTION OF THE LARGER NUMBER OF PATIENTS BEING STUDIED SO FAR, WE DON’T KNOW YET. A COUPLE OF UNUSUAL THINGS WERE UNCOVERED TODAY. ONE WAS GALLBLADDER INFLAMMATION AND ANOTHER WAS PNEUMONIA, WHICH DOESN’T REALLY MAKE A LOT OF SENSE. SO WE WILL HAVE TO STAY TUNED FOR MORE EVIDENCE OF THIS SAFETY OF IT. >> MORE THAN 76% OF AMERICAN ADULTS ARE FULLY VACCINATED. WE HAVE A BIG SUPPLY OF DOSES FOR THOSE WHO AREN’T. DO WE THINK THERE’S A NEED FOR ANOTHER VACCINE LIKE THIS? >> THIS IS REALLY IMPORTA.NT IT IS GOOD THAT SO MANY ARE VACCINEDAT, BUT 27 MILLION AMERICANS HAVE RECEIVED NO VACCINE. SO IF THIS VACCINE IS MORE ACCEPTABLE, GREAT, IWEF CAN HELP PEOPLE WHOAV HEN’T CHOSEN TO YET BE VACCINATED MAKE THE CHOICE TO GET VACCINATED, THAT IS SO IMPORTANT FOR THEM AND ALL OFS, U FOR OUR HEALTH, NOT ONLY NOW BUT AS WE GO INTO THE NEXT WINTER SEASON.

Another COVID-19 vaccine seeks approval for use in USA

Updated: 6:02 PM EDT Jun 7, 2022

Tufts infectious disease Dr. Helen Boucher explains what makes the COVID-19 vaccine Novavax different from the ones we already have.

Tufts infectious disease Dr. Helen Boucher explains what makes the COVID-19 vaccine Novavax different from the ones we already have.